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 Benzalkonium chloride (BAC), the most commonly used
preservative in ophthalmic preparations, is most often used at
a concentration of 0.01% (range 0.004%-0.02%) in topical
multidose solutions [1]. BAC is a quaternary ammonium com-
pound [2] that has been demonstrated to adversely affect both
the cornea and conjunctiva [3-5]. Several studies have sug-
gested that use of preserved drops results in a significant re-
duction of tear film breakup time, tear turnover, and an in-
crease of corneal epithelial permeability [6-8]. Although the
cytotoxic effect of BAC on corneal epithelium has been stud-
ied extensively [9-11], little is known about the effects of BAC
on precorneal mucin. Moreover, to our knowledge, there have
been no reports on the effect of BAC on mucin in the cornea.
Mucins are large, elongated molecules with a protein back-
bone to which oligosaccharides are attached [12]. Mucins are
characterized by their protein structure as secreted or mem-
brane associated. Mucin genes in humans are named MUC
and suffixed with a number indicating their order of identifi-
cation. The stratified epithelia of the human cornea produce
the membrane associated mucins MUC1 [13],13 MUC4 [14],
and MUC16 [15] which form a dense barrier in the glycocalyx
at the corneal epithelial tear film interface [16,17]. MUC1 and
MUC16 are concentrated along the apical membrane of api-
cal and subapical cells in human corneal epithelia, whereas
MUC4 mRNA is mostly found in the conjunctival epithelia
with relatively little in the central corneal epithelium [13-15].
This study examined the short term effects of BAC on
precorneal MUC1 and MUC16 in human corneal epithelium.
METHODS
Tissue and cell lines:  Immortalized human corneal-limbal epi-
thelial (HCLE) cell cultures (kindly provided by Dr. I. K.
Gipson, Schepens Eye Research Institute, Harvard Medical
School, Boston, MA) were briefly grown in keratinocyte-se-
rum free medium (K-SFM; Gibco-Invitrogen, Carlsbad, CA),
a medium optimized for keratinocyte proliferation, and were
switched at approximately half confluence to a 1:1 mixture of
K-SFM and low calcium DMEM/F12 (Gibco-Invitrogen) to
achieve confluence (about 24 h). After reaching confluence,
cells were switched to DMEM supplemented with 10% fetal
calf serum and 10 ng/ml epidermal growth factor (R&D Sys-
tems, Minneapolis, MN) for 7 days to promote stratification
and differentiation of the HCLE cells [18].
Human corneal epithelium was acquired, with consent,
as a byproduct of elective excimer photorefractive keratec-
tomy procedures. The three patients in the “BAC” group were
treated with Ocuflox® eyedrops (details of experimental so-
lutions are listed in Table 1) four times a day for 1 week be-
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fore surgery. The three patients in the control group received
no preoperative antibiotic. Anesthesia was achieved with 3
drops of proparacaine solution over a 10 min interval (every 5
min). The corneal epithelium was mechanically scraped with
a sterile Bard-Parker #15 blade. Each specimen of collected
cells was divided in two for use in PCR and western blotting.
Three corneoscleral buttons were obtained from the Yonsei
Eye Bank (Seoul, Korea) from human donor eyes. The cause
of death for the tissue donors was unknown making them un-
suitable for transplantation; the tissue appeared healthy mi-
croscopically.
The study was conducted in compliance with the provi-
sions of the Declaration of Helsinki.
RNA isolation and reverse transcription:  Total RNA was
isolated from HCLE cells and human corneal epithelium us-
ing TRIzol as the extraction reagent (Gibco-Invitrogen), ac-
cording to the manufacturer’s protocol. HCLE cells and hu-
man corneal epithelium were homogenized by adding 1 ml
reagent per well. After passing the cell lysate through a pi-
pette several times, samples were incubated at room tempera-
ture for 5 min to permit the complete dissociation of nucle-
oprotein complexes. A volume of 0.2 ml chloroform was added
to the reagent solution. Tubes were vigorously shaken by hand
and centrifuged for 15 s. The colorless upper aqueous phase
containing the RNA was recovered. Samples were then incu-
bated with 0.5 ml isopropanol and centrifuged. After remov-
ing the supernatant, the RNA pellet was washed once with
75% ethanol. The RNA pellet was dissolved in diethyl
pyrocarbonate (DEPC)-treated water and incubated for 10 min
at 60 °C. Residual genomic DNA from the samples was elimi-
nated by DNase I digestion of the RNA preparation.
cDNA synthesis (SuperScript III Reverse Transcriptase;
Gibco-Invitrogen), as described in the manufacturer’s proto-
col, used 1 µg total RNA. Oligo d(T) primers were added to
each sample then the tubes were heated to 70 °C for 10 min.
After a brief centrifugation, a mixture containing PCR buffer
(Gibco-Invitrogen), MgCl2, dNTPs, and dithiothreitol (DTT)
was added to the samples and incubated for 5 min at room
temperature. The reverse transcription was performed by add-
ing 1 µl reverse transcriptase to the mixture and incubating
the tubes at 25 °C for 10 min, 42 °C for 50 min, and 70 °C for
15 min. Samples were placed on ice for 1 min, 1 µl RNase H
was added to each tube, and they were incubated at 37 °C for
20 min. Reverse-transcription products were then ready for
use in conventional and real-time PCR reactions. Of the 20 µl
of total reverse transcription volume, 1 µl was used for each
PCR.
Conventional PCR and real-time PCR:  Conventional
polymerase chain reaction (PCR) was performed using a Perkin
Elmer RNA-PCR core kit (Roche Molecular System, Inc.,
Branchburg, NJ) in a Perkin Elmer Gene Amp PCR system
2400 (Hoffmann-La Roche Inc., Norwalk, CT). The MUC1
primers [19] and MUC16 primers [15] were designed to pro-
duce 368 bp and 114 bp PCR products, respectively. The PCR
conditions for MUC1 were an initial denaturation at 94 °C for
5 min, 35 cycles of denaturation at 94 °C for 1 min, annealing
at 65 °C for 1 min, extension at 72 °C for 1 min, and post-
elongation at 72 °C for 10 min. The PCR conditions for MUC16
were an initial denaturation at 95 °C for 10 min, 35 cycles of
denaturation at 95 °C for 15 s, annealing at 60 °C for 1 min,
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TABLE 1. EXPERIMENTAL SOLUTIONS
  Solution       BAC           Other                           Source
------------   -------   ------------------   ----------------------------------------
Control        0%        SFM
(for PCR, WB)
BAC media      0.01%     SFM
Control        0%        DW
(for TEM)
BAC solution   0.01%     DW
Ocuflox®       0.0025%   0.3% ofloxacin,      Samil Pharmaceutical, Seoul, Korea
eyedrops                 WFI
Ofloxacin      0%        0.3% ofloxacin,      Sigma-Aldrich
solution                 WFI
Alcaine®       0.01%     0.5% proparacaine,   S. A. Alcon-Couvreur Co., Puurs, Belgium
eyedrops                 WFI
Proparacaine   0%        0.5% proparacaine,   Sigma-Aldrich
solution                 WFI
For each of the experimental solutions used in these experiments, the table lists the BAC content, other components, and the source (if
purchased). Control and BAC (Sigma-Aldrich) solutions were prepared from tertiary distilled water (DW) or serum free media (SFM; Gibco-
Invitrogen). Purchased solutions were all in sterile water for injection (WFI).
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extension at 72 °C for 2 min, and post-elongation at 72 °C for
7 min. The 10 µl of PCR products were electrophoresed on
2% agarose gel containing ethidium bromide. β2 microglobulin
(β2-m) was used as an endogenous reference to determine the
integrity of the mRNA in each sample.
Real-time PCR amplification was performed in the pres-
ence of double-labeled fluorogenic probes (TaqMan probes;
PE-Applied Biosystems, Foster City, CA) that allow the rela-
tive quantification of gene expression in real time. Amplifica-
tion was performed in triplicate with 1 µl of cDNA in a total
volume of 50 µl (TaqMan chemistry; PE-Applied Biosystems).
Assays were performed using an ABI Prism 7700 Sequence
Detection System (PE-Applied Biosystems). The average
threshold cycle (CT) values for GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) were used as an internal calibrator
to correct for differences in the integrity and amount of total
RNA added to each reaction [20]. To validate the relative quan-
tification, the efficiency of the target gene amplification was
compared with the efficiency of the GAPDH amplification,
as described in the manufacturer’s protocol (PE-Applied
Biosystems). A nontemplate control was included in all the
experiments performed with real-time PCR to evaluate DNA
contamination of the reagents used for amplification. None of
the experiments resulted in a positive signal from the
nontemplate control, indicating that the RNA used in the as-
says was not contaminated by DNA.
Western blot analysis:  HCLE cells were incubated for 15
min under six different conditions: serum free media (SFM;
control group), BAC media, ofloxacin solution, Ocuflox®
eyedrops, proparacaine solution, and Alcaine® eyedrops.
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Figure 1. MUC1 and MUC16 gene expression in human corneal-
limbal epithelial (HCLE) cells.  A: No differences were detected quali-
tatively in the expression of MUC1 and MUC16 mRNA among groups
in conventional RT-PCR. β2 microglobulin (β2-m) was a housekeep-
ing gene for the conventional RT-PCR. B: Real time RT-PCR dem-
onstrated that there was no significant difference in the amount of
MUC1 transcripts between the control group and the BAC media
treatment group (p=0.827), between the Ocuflox® eyedrops and
ofloxacin solution treatment groups (p=0.275), and between the
Alcaine® eyedrops and proparacaine solution treatment groups
(p=0.400). C: Real time RT-PCR demonstrated that there was no
significant difference in the amount of MUC16 transcripts between
the control group and the BAC media treatment group (p=0.187),
between the Ocuflox® eyedrops and ofloxacin solution treatment
groups (p=0.275), and between the Alcaine® eyedrops and
proparacaine solution treatment groups (p=0.377). The graphs show
the mean values of three independent experiments; the error bars
represent the standard deviation.  
Figure 2. MUC1 and MUC16 gene expression in human corneal epi-
thelium.  A: Conventional RT-PCR demonstrated no differences in
MUC1 and MUC16 mRNA expression between the Ocuflox®
eyedrops treatment and control group. Corneal epithelia were treated
with Ocuflox® eyedrops or with nothing (control). B: The graphs
show the mean values of three independent experiments; the error
bars represent the standard deviation. Values were normalized to the
density of the respective band of β2 microglobulin (β2-m).  
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HCLE cells and human corneal epithelium were lysed in buffer
(25 mM HEPES pH 7.5, 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.05% Triton X-100, 0.5 mM DL-Dithiothreitol, 0.4
mM PMSF, 2 µg/ml leupeptin, and 1 µg/ml pepstatin A). Pro-
teins at each purification step were subjected to SDS poly-
acrylamide gel electrophoresis [21] using a 6% separating,
4% stacking gel followed by electroblotting on Immobilon™-
P polyvinylidene difluoride (PVDF) membranes (Millipore
Corp., Bedford, MA). The membranes were washed with Tris
buffered saline and treated with 0.1 U/ml of Type V neuramini-
dase (Sigma-Aldrich, St. Louis, MO) in a 50 mmol sodium
acetate and 10 mmol calcium acetate buffer (pH 6.5) at 37 °C
for 1 h. The blots were then exposed to monoclonal antibod-
ies recognizing MUC1 (HMFG-1, 1:1000; Biodesign, Saco,
ME) [13] or MUC16 (OC125, 1:1000; Dako Corp.,
Carpinteria, CA) [15] overnight at 4 °C. After removing the
antibodies and washing the reactive proteins, the membrane
was treated with peroxidase conjugated antimouse IgG (1:1000
dilution; Amersham Pharmacia Biotech, Buckinghamshire,
England). Detection was carried out using enhanced chemilu-
minescence (ECL) detection reagents (Amersham Pharmacia
Biotech, Piscataway, NJ) on Hyperfilm ECL (Amersham
Pharmacia Biotech [USA]). β-actin was used as an endog-
enous reference to determine the integrity of the protein in
each sample.
Preparation of corneal tissue for transmission electron
microscopy:  Three human corneas were dissected from
corneoscleral buttons. Each human cornea was divided into
six pieces; a negative control was fixed overnight in a 5%
glutaraldehyde (containing 0.1 M sodium cacodylate-HCl and
1% sucrose at pH 7.4). A positive control was fixed overnight
in 5% glutaraldehyde (containing 0.1 M sodium cacodylate-
HCl and 1% sucrose at pH 7.4) with 0.5% cetylpyridinium
chloride (CPC). Four pieces were treated with 0.01% BAC
solution diluted in tertiary distilled water for 1, 5, 15, or 60
min at 4 °C. Treated corneas were fixed overnight in a 5%
glutaraldehyde (containing 0.1 M sodium cacodylate-HCl and
1% sucrose, pH 7.4). After fixation, all specimens were washed
in 0.15 M sodium cacodylate-HCl, pH 7.3, and fixed again
for 1 h at room temperature in 1% glutaraldehyde in 0.1 M
sodium cacodylate-HCl with 1% tannic acid. They were
washed again in 0.1 M sodium cacodylate-HCl and were
postfixed in Palade’s buffer containing 2% osmium tetroxide
for 1 h at 4 °C. Finally, corneas were dehydrated in ethanol,
and embedded in Epon [21,22].
Transmission electron microscopy:  Thin sections were
cut with a diamond knife using a LEICA ultracut microtome,
stained with aqueous uranyl acetate and Reynolds lead citrate
(or with the latter alone), and examined in a Philips CM-10
microscope operating at 80 KV with a 60 µm objective aper-
ture.
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Figure 3. Western blot and densitometric analyses.  Western blotting
was used to measure MUC1 and MUC16 in both human corneal-
limbal epithelial (HCLE) cells and human corneal epithelium ex-
posed to different concentrations of benzalkonium chloride (BAC).
HCLE cells (A,B) exposed to BAC had decreased MUC1 and MUC16
protein levels (p<0.05). There is the suggestion of a concentration
response in the data, but the data set is not suitable for a statistical
test of trend. The human corneal epithelium (C) of patients treated
with Ocuflox® eyedrops also had a decrease in MUC1 and MUC16
protien levels (p<0.05). A: The bar graph shows the quantity of MUC1
(relative to β-actin) in the six groups: control, BAC media, ofloxacin
solution, Ocuflox® eyedrops, proparacaine solution, and Alcaine®
eyedrops. B: The bar graph shows the quantity of MUC16 (relative
to β-actin) in the same six groups. C: The bar graph shows the quan-
tities of MUC1 and MUC16 (relative to β-actin) in the control and
Ocuflox® eyedrops groups. The values in these graphs represents
the mean of three experiments; the error bars represent the standard
deviation. Values were normalized to the density of the respective
band of β-actin.    
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Statistics:  Statistical differences between measured
mRNA and protein levels were assessed using parametric test-
ing with SPSS (version 12). An α level of 0.05 was chosen for
all tests.
RESULTS
MUC1 and MUC16 mRNA expression in HCLE cells and
human corneal epithelia: The expression of MUC1 and
MUC16 mucin gene transcripts in corneal epithelia was ini-
tially determined by conventional RT-PCR (Figure 1A). Am-
plification of cDNA products from HCLE cells treated with
serum free media (control), HCLE cells treated with BAC
media, HCLE cells treated with ofloxacin solution, HCLE cells
treated with Ocuflox® eyedrops, HCLE cells treated with
proparacaine solution, and HCLE cells treated with Alcaine®
eyedrops produced bands corresponding to the MUC1 and
MUC16 sizes that qualitatively had the same density (Figure
1A). The housekeeping gene β2-m was used to normalize the
results.
The use of real-time PCR demonstrated that no change
was detected in the expression of the MUC1 and MUC16
mRNA by the treatment with BAC in HCLE cells (Figure
1B,C). The amount of MUC1 and MUC16 transcripts was not
significantly different between the control group and the BAC
media treatment group (Figure 1B,C). Levels of the MUC1
and MUC16 mRNA remained essentially unaltered after treat-
ment with Ocuflox® eyedrops and Alcaine® eyedrops com-
pared to ofloxacin solution and proparacaine solution treat-
ment groups, respectively (Figure 1B,C).
The expression of MUC1 and MUC16 mucin gene tran-
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Figure 4. Transmission electron microscopy.  Transmission electron
micrographs of human corneas treated with 0.01% BAC solution. A:
The negative control cornea (no BAC) showed no mucous layer. B:
The positive control cornea fixed with CPC showed a well defined
mucous layer. C: Cornea treated with BAC solution for 5 min showed
a thin trace of mucous layer on the surface. D: Corneas treated with
BAC solution for 15 min showed a thinned mucous layer. E: Cor-
neas treated with BAC solution for 60 min had a near total loss of the
mucous layer. The mucous present was mostly seen clumped near
the epthelium, but no longer attached to it. Scale bars represent 1
µm.
 A B
C D
E
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scripts in human corneal epithelium was determined by con-
ventional RT-PCR. The steady-state levels of the two mucins
were not decreased in human corneal epithelium that had been
treated with Ocuflox® eyedrops for a week (Figure 2).
MUC1 and MUC16 in HCLE cells and human corneal
epithelia:  Western blot analysis was performed to determine
the effect of BAC on MUC1 and MUC16. Figure 3A showed
a reduction of MUC1 in the group treated with BAC media
compared to the control group. A reduction of MUC1 was also
observed in the Ocuflox® eyedrops and Alcaine® eyedrops
treatment groups (Figure 3A). The group treated with 0.0025%
BAC (Ocuflox® eyedrops) has a tendency to show less re-
duction of MUC1 than groups treated with 0.01% BAC
(Alcaine® eyedrops, BAC media). Figure 2B shows the west-
ern blot analysis of MUC 16; as with MUC1, the MUC16 was
also decreased in groups treated with BAC. Also, the higher
concentration of BAC resulted in a greater reduction of
MUC16 (Figure 3B). Experiments using three human corneal
epithelia demonstrated that the groups that received Ocuflox®
eyedrops for 1 week before surgery had a lower level of MUC1
and MUC16 than the control group (Figure 3C).
Transmission electron microscopy of human corneas ex-
posed to BAC:  The mucous layer was absent in negative con-
trol corneas (Figure 4A) and the group treated with 0.01%
BAC solution for 1 min (data not shown). The positive con-
trol corneas fixed with CPC demonstrated a well-defined
mucous layer 0.55 µm thick (standard deviation 0.116 µm;
Figure 4B). The corneas treated with BAC solution for 5 min
had a thin mucous layer on the surface (Figure 4C). A definite
mucous layer was observed in the corneas treated with BAC
solution for 15 min (Figure 4D). When treated with BAC so-
lution for 60 min, corneas had diffuse damage to the epithelial
cell layer; the mucous layer was essentially lost and what
mucous remained was no longer adherent to the epithelium
(Figure 4E).
DISCUSSION
 In our clinical experience, even a single eyedrop containing
BAC can cause conjunctival injection and ocular irritation.
Ishibashi et al. [6] have shown that an eyedrop containing
0.005% BAC significantly reduces the tear film breakup time
for 30 min after instillation. This indicates that BAC destabi-
lizes the tear film [23]. The current model of the tear film
suggests that there is a superficial lipid layer above an aque-
ous layer that contains secreted mucins and membrane asso-
ciated mucins that have been shed [24]. The glycocalyx is made
up of the extracellular domains of the membrane associated
mucins (MUC1, MUC4, and MUC16) on the apical corneal
epithelial cells with the aqueous phase of the tear film in con-
tact with the glycocalyx [25]. The hydrophilic nature of mu-
cins is important in maintaining the tear film because it keeps
water on the corneal surface [26]. We report alterations in the
precorneal mucins after short term exposure to BAC.
By using a combination of conventional and real-time RT-
PCR, we demonstrated that BAC exposure did not alter the
expression of MUC1 and MUC16 mRNA in a cell culture
model (Figure 1). Nor is the expression of MUC1 and MUC16
affected in patients using Alcaine® eyedrops (Figure 2) in con-
ventional RT-PCR. These suggest that any reduction of MUC1
and MUC16 following BAC exposure is not a result of gene
regulation in our cell culture model or in patients’ corneal epi-
thelia.
The western blot analysis assessed the effect of BAC on
the amount of MUC1 and MUC16 in a cell culture model. We
found a significant reduction of MUC1 and MUC16 after ex-
posure to BAC for only 15 min (Figure 3). Experiments using
patient corneal epithelia demonstrated that the groups that re-
ceived Ocuflox® eyedrops for 1 week before surgery had a
lower level of mucins than the control group (Figure 3).
Our TEM results demonstrated a thin mucous layer after
treatment with 0.01% BAC solution for as little as 5 min. With
longer exposures to BAC solution, the observable mucous layer
was noticably thicker. However, after exposures to BAC solu-
tion for about an hour, the mucous layer is disrupted and there
is diffuse damage to superficial epithelial cells across the cor-
nea. Why does this layer appear with exposure to BAC solu-
tion? Conventional electron microscopy techniques do not
preserve the mucous layer. Nichols et al. [21] demonstrated
the mucous layer on the corneal epithelium by using quater-
nary ammonium compounds (e.g., CPC) to fix the mucous for
TEM processing. Quaternary ammonium compounds fix
soluble acid mucopolysaccharides (e.g., mucin) by forming
highly insoluble complexes [27]. We theorize that exposure
to BAC (another quaternary ammonium compound [2]), fixes
the mucin within the mucous layer leading to the visualiza-
tion of the mucous layer under TEM (Figure 4). As our BAC
solution was not part of an optimized fixation protocol like
the CPC used in the positive control (Figure 4B), we believe
that it was an inefficient fixative and that prolonged exposure
to it ultimately did not preserve the layer for electron micro-
scopic staining. Thus, it is possible the loss of mucins in the
western blot analysis corresponds to the fixation of mucin with
the alteration of its structure to the point that antibodies do not
bind to it.
The decrease in the amount of functional mucin on the
corneal surface may affect the stability of the tear film. Mu-
cins contribute to the formation of highly hydrated gel struc-
tures, mainly through the hydrophilic O-linked oligosaccha-
ride side chains. A mucus gel with 0.5-5% mucins can contain
90% water [28]. Loss of the mucous layer may lead to de-
creased water retention and consequently to the ocular irrita-
tion symptoms commonly associated with the use of eyedrops
containing BAC. It may itself contribute directly to epithelial
damage. In a TEM study of rabbit cornea, damaged corneal
epithelial cells were seen to slough off after a 1.5 h exposure
to BAC solution [29].
In conclusion, BAC can alter the precorneal mucin and
seems likely to cause tear film dysfunction. As BAC remains
in wide use, it is worthwhile to continuously re-evaluate its
use in patients with ocular surface disorders. Eliminating BAC
may be desirable to protect the tear film, but must be weighed
against the potential dangers of unpreserved eyedrops.
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